Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?

Investors turned away from Moderna in recent years as its blockbuster coronavirus vaccine saw declining demand. The company's pipeline progress looks promising today, sparking fresh optimism among investors.